Weight Loss in Adults Using Semaglutide (Real-world Study)

Novo Nordisk A/S237,211 enrolled

Overview

The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.

Study Type

OBSERVATIONAL

Enrollment

237,211

Conditions

Overweight Obesity

Interventions

SemaglutideDRUG

This is a retrospective, non-interventional study; therefore, no intervention was administered as part of the study.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Initiation of semaglutide for weight management during the study period. * Age more than or equal to (≥) 18 at treatment initiation * Baseline body mass index (BMI) ≥27 and less than (\<) 30 kilogram per meter square (kg/m\^2) with at least one weight-related comorbidity, or BMI ≥30 kg/m\^2. * Other inclusion criteria as defined in the protocol are applicable. Exclusion Criteria: * Prior use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) based medication or other obesity management medication (OMMs). * Bariatric surgery at baseline. * Diabetes at baseline. * Pregnancy at baseline.

Locations (2)

Novo Nordisk Investigational Site

Seattle, Washington, United States

Novo Nordisk Investigational Site

London, United Kingdom

Outcomes

Primary Outcomes

Change in body weight

Measured as kilogram (kg)

Time frame: From index date (day 0) to week 68 (day 476)

Change in body weight

Measured as percentage (%)

Time frame: From index date (day 0) to week 68 (day 476)

Proportion of individuals achieving a clinically meaningful weight loss

Binary (yes/no): estimated ≥5% reduction from baseline body weight

Time frame: From index date (day 0) to week 68 (day 476)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.